SCHEMBL2498356

SCHEMBL2498356

COc1cccc(NCCCS(=O)(=O)O)c1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 1/20 0.59
MTNR1B P49286 1/20 0.59
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
GAA P10253 1/20 0.48
ICMT O60725 1/20 0.46
RAB9A P51151 1/20 0.46
TSHR P16473 2/20 0.46
TP53 P04637 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
POLB P06746 1/20 0.45
LMNA P02545 2/20 0.45
HPGD P15428 2/20 0.45
ALDH1A1 P00352 1/20 0.45
PKM P14618 1/20 0.45
USP2 O75604 1/20 0.45
HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL244918 0.86 KMT2A (0.42) MTNR1AMTNR1BKMT2AMEN1SMN1; SMN2
SCHEMBL6259332 0.85 MAPT (0.49) MTNR1AMTNR1BKMT2ASMN1; SMN2RAB9A
SCHEMBL27677191 0.85 KMT2A (0.41) MTNR1AMTNR1BKMT2AMEN1SMN1; SMN2
Water SCHEMBL20853621 0.84 KMT2A (0.41) MTNR1AMTNR1BKMT2AMEN1SMN1; SMN2
SCHEMBL917492 0.83 GAA (0.59) KMT2AMEN1SMN1; SMN2GAARAB9A
SCHEMBL6404606 0.83 MTNR1A (0.56) MTNR1AMTNR1BKMT2AMEN1SMN1; SMN2
SCHEMBL5587045 0.83 KMT2A (0.42) MTNR1AMTNR1BKMT2AMEN1SMN1; SMN2
SCHEMBL12311324 0.83 MTNR1A (0.53) MTNR1AMTNR1BKMT2AMEN1SMN1; SMN2
SCHEMBL11114174 0.82 MTNR1A (0.66) MTNR1AMTNR1BKMT2AMEN1GAA
SCHEMBL1897682 0.82 MAPT (0.61) KMT2AMEN1GAAICMTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012168470-A1 METHOD FOR THE DETERMINATION OF THE CONCENTRATION OF VITAMIN B6 IN A SAMPLE BÜHLMANN LABORATORIES AG (CH) 2012-12-13 WO claimed
CN-118302536-A Reagent composition and kit 电化株式会社 2024-07-05 CN disclosed
EP-4029949-B1 KIT AND A METHOD FOR QUANTIFYING SMALL DENSE LDL CHOLESTEROL (SDLDL-C) IN A SAMPLE DENKA COMPANY LTD (JP) 2024-07-03 EP disclosed
CN-112074743-B Method, reagent and kit for quantifying lipoprotein cholesterol 电化株式会社 2024-04-12 CN disclosed
EP-4328320-A1 REAGENT COMPOSITION AND KIT Denka Company Limited (JP) 2024-02-28 EP disclosed
CN-117203347-A Reagent composition and kit 电化株式会社 2023-12-08 CN disclosed
EP-3467120-B1 METHOD AND REAGENT FOR QUANTIFYING CHOLESTEROL IN TRIGLYCERIDE-RICH LIPOPROTEIN DENKA COMPANY LTD (JP) 2023-11-08 EP disclosed
WO-2023199890-A1 REAGENT COMPOSITION AND KIT デンカ株式会社 2023-10-19 WO disclosed
US-20230313266-A1 METHOD AND KIT FOR QUANTIFICATION OF LIPOPROTEIN CHOLESTEROL DENKA COMPANY LIMITED (JP) 2023-10-05 US disclosed
CN-109312389-B Method for quantifying cholesterol in triglyceride-rich lipoprotein and quantification reagent 电化株式会社 2023-09-19 CN disclosed
EP-2116612-A1 REAGENT FOR DETERMINATION OF QUANTITY OF SMALL DENSE LOW-DENSITY LIPOPROTEIN DENKA SEIKEN Co., Ltd. (JP) 2009-11-11 EP disclosed
US-20090263844-A1 METHOD AND KIT FOR QUANTITATIVE DETERMINATION FOR SMALL, DENSE PARTICLE LOW DENSITY LIPOPROTEINS DENKA SEIKEN CO., LTD. (JP) 2009-10-22 US disclosed
EP-1930442-A1 METHOD AND KIT FOR QUANTITATIVE DETERMINATION FOR SMALL, DENSE PARTICLE LOW DENSITY LIPOPROTEINS DENKA SEIKEN Co., Ltd. (JP) 2008-06-11 EP disclosed
US-20040247629-A1 Anhydrous cosmetic makeup composition containing a fatty phase and a cosmetic treatment process using the composition L'OREAL 2004-12-09 US disclosed
US-6572870-B2 Mixture containing oils, lipids and surfactants L'OREAL (FR) 2003-06-03 US disclosed
US-20010055601-A1 Anhydrous cosmetic makeup composition containing a fatty phase and a cosmetic treatment process using the composition L'OREAL 2001-12-27 US disclosed
US-6319508-B1 ANHYDROUS COSMETIC MAKEUP COMPOSITION FOR APPLICATION TO SKIN OR LIPS CONSISTING ESSENTIALLY OF MIXTURE OF FATTY PHASE AND PROVESICULAR LIPID PHASE ALSO CONTAINING AT LEAST ONE COSMETIC AND/OR DERMOPHARMACEUTICAL ACTIVE MATERIAL L'OREAL (FR) 2001-11-20 US disclosed
EP-0398941-A4 DRY POWDER DIAGNOSTIC REAGENT AND APPLICATIONS THEREOF 1991-04-10 EP disclosed
EP-0398941-A1 DRY POWDER DIAGNOSTIC REAGENT AND APPLICATIONS THEREOF BOEHRINGER MANNHEIM CORPORATION (US) 1990-11-28 EP disclosed
WO-1989006284-A1 DRY POWDER DIAGNOSTIC REAGENT AND APPLICATIONS THEREOF BOEHRINGER MANNHEIM CORPORATION (US) 1989-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010055601-A1 Anhydrous cosmetic makeup composition containing a fatty phase and a cosmetic treatment process using the composition FABP4, CUTA, LIPA MTNR1A 3827/4885MTNR1B 3950/4885KMT2A 3327/4885
US-20040247629-A1 Anhydrous cosmetic makeup composition containing a fatty phase and a cosmetic treatment process using the composition FABP4, CUTA, LIPA MTNR1A 3827/4885MTNR1B 3950/4885KMT2A 3327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.